Psoriatic Skin Lesions after Apalutamide Treatment


  • Fumi Miyagawa Nara Medical University
  • Nobuya Akioka
  • Noriko Yoshida
  • Kohei Ogawa
  • Hideo Asada



Abstract is missing (Short communication)


Download data is not yet available.


Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018; 378: 1408-1418.

Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019; 381: 13-24.

Schwarz W, Schell H, Hornstein OP. Testosterone serum levels in male psoriatics. Arch Dermatol Res 1981; 270: 377-379.

Cemil BC, Cengiz FP, Atas H, Ozturk G, Canpolat F. Sex hormones in male psoriasis patients and their correlation with the Psoriasis Area and Severity Index. J Dermatol 2015; 42: 500-503.

Allam JP, Bunzek C, Schnell L, Heltzel M, Weckbecker L, Wilsmann-Theis D et al. Low serum testosterone levels in male psoriasis patients correlate with disease severity. Eur J Dermatol 2019; 29: 375-382.

Rathkopf DE, Scher HI. Apalutamide for the treatment of prostate cancer. Expert Rev Anticancer Ther 2018; 18: 823-836.

Shima K, Nomura T, Yamada Y, Usui S, Kobayashi T, Kabashima K. Maculopapular-type drug eruptions caused by apalutamide: case series and a review of the literature. J Eur Acad Dermatol Venereol 2022; 36: e113-e115.




How to Cite

Miyagawa, F., Akioka, N., Yoshida, N., Ogawa, K., & Asada, H. (2022). Psoriatic Skin Lesions after Apalutamide Treatment. Acta Dermato-Venereologica, 102, adv00659.



Short Communication